26 results about "Beta-Cyclodextrins" patented technology

The invention belongs to the technical field of external diagnosis devices, and particularly relates to a memristor for adenovirus concentration detection and a preparation method of the memristor. The memristor comprises a bottom electrode layer, a metal oxide layer, a functional layer and an upper electrode layer which are sequentially formed from bottom to top in the thickness direction, the bottom electrode layer is an FTO conductive glass layer, the metal oxide layer is tantalum pentoxide, the functional layer is a gelatin-beta cyclodextrin composite film, and the upper electrode layer is a conductive electrode layer. The gelatin-beta cyclodextrin composite film with the memristive effect serves as a functional layer, after the film makes contact with adenoviruses, the film adsorbs virus particles, then the unique resistance change characteristic of the memristor is caused, the memristive behavior of the memristor is further fed back, and the memristive effect of the memristor is improved. The method is used for recording and analyzing the electrochemical or bio-electricity signal characteristics of adenovirus solutions with different concentrations, the adenovirus solutions with different concentrations are effectively distinguished according to the electric signal difference of the adenovirus solution and the control solution, the effect is obvious, and the repeatability is good.

The invention relates to the technical field of analysis and test technologies and medical methods, and discloses a reagent and a method for molecular structure analysis of an estrogen isomer, which are based on cyclodextrin and are used for molecular structure analysis of an alpha / beta-E2 / E3 isomer. The reagent comprises gamma cyclodextrin (gamma-CD), beta-CD and a mixed aqueous solution of compounds containing different metal ion ligands, the molecular formula of the beta-CD is C42H70O35, the molecular weight of the beta-CD is 1134.98, and the compound containing the metal ions is salt of any metal ion or soluble alkali containing the metal ions. According to the method, an alpha / beta-E2 / E3 sample, CD, a compound containing metal ions, such as monovalent metal or divalent metal ions and the like are simply prepared into a mixed solution, then non-covalent compound ions of alpha / beta-E2 / E3-gamma-CD / beta-CD-containing metal ions are generated by utilizing electrospray ionization, and then the ion mobility spectrometry of the non-covalent compound ions is measured by utilizing an ion mobility spectrometry technology. And different position structure information of alpha / beta-E2 / E3 molecules can be obtained.

The present application provides a milbemycin oxime praziquantel-based parasitic expelling drug, which comprises the following components in parts by mass: modified milbemycin oxime 10-30 parts, nano-coated praziquantel 20-50 parts, compound synergist 5-15 parts, flavoring agent 3-8 parts, and disintegrating agent 2-5 parts. The application of the milbemycin oxime praziquantel-based parasitic expelling drug is used for preparing a preparation for preventing or treating mixed parasitic infection of dogs and cats, wherein the parasites include tapeworms, nematodes, trematodes and Demodex. Through the integrated innovation of chemical modification (succinylated milbemycin oxime), nanotechnology (HPMC-coated praziquantel) and compound synergy (non-ban Tai'er-beta cyclodextrin), the comprehensive advantages of broad-spectrum parasitic expelling, long-acting stability, safety and low toxicity are realized, and the pain points such as poor palatability, high metabolic burden and weak environmental adaptability in the prior art are solved, and the application is suitable for the prevention and treatment of mixed parasitic infection of dogs and cats.

The invention relates to the technical field of food processing, in particular to a functional oligosaccharide-containing glycolipid double-control composite tablet candy, which is prepared from the following raw materials: functional oligosaccharide, a lipid control component, a sweet base, microcrystalline cellulose, magnesium stearate, monoglyceride and beta cyclodextrin, the functional oligosaccharide is selected from one or more of fructo-oligosaccharide, isomaltooligosaccharide and galactooligosaccharide; the fat control component is selected from one or more of phytosterol ester and conjugated linoleic acid glyceride; the sweet base material comprises maltitol and isomaltulose; the raw materials can also comprise a mulberry leaf extract. According to the invention, a compound system of the functional oligosaccharide, the special fat control component and the auxiliary sugar control component is adopted, and all the components form a synergistic effect, so that not only can the glycemic index be effectively reduced, but also the fat absorption can be obviously inhibited, the double control of the sugar and the fat in a real sense is realized, and compared with the existing single-function product, the efficacy is more comprehensive and more obvious.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a 4-aminopyridine sustained release preparation and a preparation method thereof. The sustained release preparation comprises 4-aminopyridine, ethyl-beta cyclodextrin-calcium carbonate microspheres, a filler, an adhesive, a disintegrating agent and a lubricant. According to the sustained-release preparation, the sustained-release time can be prolonged, the medicine taking frequency is reduced, the content uniformity of the preparation is improved, meanwhile, the preparation process is improved, and stimulation to operators, environment control in a production workshop and equipment cost are reduced.

The application provides a polyethylene glycolized recombinant canine human uricase injection preparation and a preparation method thereof. The injection preparation is composed of polyethylene glycolized recombinant canine human uricase, a beta cyclodextrin derivative, a buffer and an osmotic pressure regulator. The preparation method comprises the steps of solution preparation, sterilization, canning, plug pressing and the like. The polyethylene glycolized recombinant canine human uricase injection of the application has high purity, few impurities and little PEG residue, avoids the problem of increased drug immunogenicity after PEG shedding, and has high stability; compared with a freeze-drying preparation, the production process is simple, the production cycle is short, the freeze-drying process is not needed, and the energy consumption is low.

The utility model discloses a glucosyl stevioside production device, and relates to the technical field of glucosyl stevioside production, an inlet of a conversion tank is communicated with a raw material tank, a cyclodextrin tank, a beta cyclodextrin transferase tank and a first alkali liquor tank, and an outlet of the conversion tank is communicated with a reaction tank; an inlet of the reaction tank is respectively communicated with a sucrose tank, a sucrose synthase tank, a uridine diphosphate tank, a UGT glycosyltransferase tank and a second alkali liquor tank through pipelines, an outlet of the reaction tank is communicated with a cation exchange resin column, an inlet of the cation exchange resin column is communicated with an ethanol tank, an outlet of the cation exchange resin column is communicated with a concentration tank, and the concentration tank is communicated with a second alkali liquor tank. An outlet of the concentration tank is communicated with a dryer, and an outlet of the dryer is communicated with a glucosyl stevioside tank. The residue of unreacted glucoside in the glucosyl stevioside is reduced through a double-enzyme method, the conversion rate of a substrate is improved, the residue of the substrate is further reduced, and the taste of the product is integrally improved.

Inclusion complex comprising an active pharmaceutical ingredient which is a P2X7 inhibitor receptor antagonist (e.g. lidocaine hydrochloride, articaine) and a cyclodextrin (e.g. HP beta cyclodextrin) for use in the treatment of an autoimmune disease or a condition in which an immune response caused by a disease or infection causes hyperinflammation (e.g. Long COVID) wherein the inclusion complex is presented for administration to the lymphoid system. A base (e.g. sodium bicarbonate) may be further included in the inclusion complex. Inclusion complex may be administered intra- or sub-dermal or subcutaneously, e.g. by infusion pump or pen injector. Also claimed is a formulation comprising an inclusion complex, said complex comprising lidocaine.HCl or articaine.HCl, hydroxypropylated β-CD, a pH modifier and water wherein the pH is 5-7.4 and the ratio and concentration of components is further limited. Said formulation may have a shelf life of at least 32 weeks based on accelerated testing at 60 °C.

The application relates to a preparation method of a networked amidoxime beta cyclodextrin adsorbent, which comprises the following steps: first, carrying out a first step reaction of beta-cyclodextrin and epichlorohydrin; then, adding acrylonitrile to carry out a second step reaction under a nitrogen atmosphere to obtain a networked beta-cyclodextrin acrylonitrile polymer; and finally, carrying out a third step reaction of the networked beta-cyclodextrin acrylonitrile polymer and hydroxylamine hydrochloride to obtain a networked beta-cyclodextrin amidoxime polymer. The synthesis steps are simple, water is used as a reaction medium (avoiding the use of a large amount of organic solvents), and the environment is good; the prepared adsorbent has excellent selectivity for gallium in Bayer mother liquor; the adsorption capacity of the adsorbent for gallium ions reaches 41.6 mg / g or more, and the saturated adsorption time is extremely short, which is 6 minutes; the adsorbent has excellent adsorption kinetics; in addition, the adsorbent has a stable structure, the adsorbent can be made into a liquid filter paper, has a long service life in the Bayer mother liquor, and the adsorption capacity retention rate is not less than 90% after 5 adsorption-desorption cycles.

The invention provides ChS-betaCD as well as a preparation method and application thereof, and particularly provides application of a preparation in preparation of a medicine, the medicine is used for preventing and / or treating tumors caused by STING protein function defects, and the preparation comprises a beta cyclodextrin-chondroitin sulfate conjugate. The formulations further comprise a STING agonist, such as cGAMP. The preparation provided by the invention has organelle targeting and intracellular cholesterol distribution regulation ability, promotes STING transport and activation, induces immune response and generates lasting immune memory, and plays an anti-tumor effect. Meanwhile, the preparation provided by the invention can effectively reduce the cytotoxicity of beta-cyclodextrin, and has a good application prospect.

A composition includes water; a eutectic solvent; and unmodified beta cyclodextrin. A method of making a composition includes combining a hydrogen bond acceptor, a hydrogen bond donor, and unmodified beta cyclodextrin to form a eutectic solvent, wherein the hydrogen bond acceptor comprises a monosaccharide, a disaccharide, or a sugar alcohol; and adding the eutectic solvent to water and a perfume, forming the composition.

The invention relates to the technical field of cyclodextrin detection, and discloses a method for detecting cyclodextrin in fermented grains based on a UHPLC-CAD (Ultra High Performance Liquid Chromatography-Computer Aided Design) technology, which comprises the following steps of: optimizing chromatographic column selection and detection parameters of a high performance liquid chromatograph and detection parameters of an electric fog type detector by adopting an ultra high performance liquid chromatograph and electric fog type detector combined system; in cooperation with pretreatment of a sample in the fermented grains, qualitative and quantitative detection of alpha cyclodextrin, beta cyclodextrin and gamma cyclodextrin in the fermented grains at the same time is successfully realized; the separation effect is excellent, interference is small, the detection speed is high, and the internal relation between the starch content, the dextrin content and the gelatinization degree in the fermented grains can be deeply excavated.

The application provides a eugenol-based tobacco bud inhibitor preparation and a compounding reduction-increase efficiency method thereof, and belongs to the technical field of tobacco bud inhibitor preparation. The specific process comprises the following steps: first, forming a clathrate of the eugenol mixture and beta cyclodextrin to realize molecular level protection; then, mixing the clathrate with gelatin and arabic gum to prepare an aqueous solution, adding chitosan to form a stable emulsion, and precisely controlling the particle size by using microemulsion technology; then, adding ultraviolet absorbers and antioxidants to enhance the environmental stability, and preparing core-shell structure microcapsules by optimizing the parameters of the spray drying method; finally, mixing the microcapsules with corn starch and dispersants to form the final slow-release product, thereby successfully solving the technical problems of poor stability, large volatile loss and limited application of the eugenol mixture used for tobacco bud inhibitor, and reducing the use of chemical bud inhibitor 2-chloro-3, 3- dimethyl-1-propene.

A composition includes water; a eutectic solvent; and unmodified beta cyclodextrin. A method of making a composition includes combining a hydrogen bond acceptor, a hydrogen bond donor, and unmodified beta cyclodextrin to form a eutectic solvent, wherein the hydrogen bond acceptor comprises a monosaccharide, a disaccharide, or a sugar alcohol; and adding the eutectic solvent to water and a perfume, forming the composition.

The present application relates to the technical field of dressings, in particular to a composite dressing patch based on glucomannan and a preparation method thereof. First, glucomannan is compounded with alpha cellulose, so that the structural functional group -OH on the alpha cellulose chain and the hydrogen bond network formed by the glucomannan in water act, the functional group -OH extends outward along the cellulose molecular structure, thereby realizing that the cellulose molecules are inserted in the glucomannan network structure, and the mechanical strength of the glucomannan hydrogel is enhanced. Secondly, amino beta cyclodextrin treated by amino functionalization is selected and grafted to the functional group -OH of the glucomannan and alpha cellulose through citric acid. Finally, the drug curcumin is dispersed in the mixed solution. Since the beta-cyclodextrin has a hydrophobic cavity, it can load the hydrophobic curcumin through host-guest interaction, thereby preparing a dressing patch with good sustained release effect and moisturizing effect.

The invention belongs to the technical field of biomass carbon materials, and discloses a bamboo-based biochar composite material and a preparation method thereof.The method comprises the steps that bamboo powder serves as a raw material, a deep eutectic solvent system composed of choline chloride and urea according to the molar ratio of 1: 2 is adopted, and a functional small molecule composite system composed of lactic acid and ethanolamine is introduced; the bamboo powder is subjected to esterification and ammoniation pretreatment to construct nitrogen-oxygen functionalized active sites, meanwhile, beta cyclodextrin is added as a degradable green template agent, and the beta cyclodextrin is self-degraded in the carbonization process to form a hierarchical porous structure. The bamboo-based biochar obtained after drying, carbonization and composite modification has high specific surface area, high functional group density and excellent adsorption performance. The method does not need acid-base activation, is green in process and low in energy consumption, has a hierarchical pore structure and chemical functionalization characteristics, and is suitable for wastewater heavy metal adsorption, gas purification and catalytic carrier application.

The application discloses a compound acidity regulator and a preparation method thereof, and relates to the field of acidity regulators. The compound acidity regulator comprises the following components in percentage by weight: modified glacial acetic acid: 25-35%, citric acid: 8-12%, lactic acid: 8-12%, DL-malic acid: 3-7%, and the rest is purified water; the modified glacial acetic acid is prepared by inclusion of glacial acetic acid molecules by beta cyclodextrin. The preparation method comprises the following steps: diluting the modified glacial acetic acid by adding 55-65% of the formula amount of purified water under a low-temperature environment; sequentially adding citric acid, lactic acid and DL-malic acid, and the interval time between two adjacent acids is 5-10 min; uniformly dispersing by high-speed stirring; adding the remaining purified water, and continuously stirring at high speed until colorless and transparent, so as to obtain the compound acidity regulator. The application can realize the synergistic optimization of acidity intensity, flavor softness, dissolution rate and storage stability.

The invention belongs to the technical field of plant extraction, and particularly relates to an efficient extraction and purification process of total glycosides of centella asiatica, which comprises the following preparation steps: crushing dried centella asiatica, adding a specific degreasing agent into the crushed centella asiatica, stirring, centrifuging, drying and collecting centella asiatica powder; adding a mixed functional enzyme and pure water, adjusting the pH value to 5-6.5, carrying out enzymolysis at 45-55 DEG C for 2-4 hours, and carrying out enzyme deactivation, concentration and drying, so as to obtain an enzymolysis centella asiatica solid; adding an extraction solution, heating, stirring and separating to obtain supernate and a solid, adding the extraction solution into the solid, repeatedly extracting for 1-2 times, combining the supernate, adding modified beta-cyclodextrin, and stirring to obtain a centella asiatica extracting solution; concentrating the centella asiatica extracting solution into paste, performing alcohol precipitation, removing ethanol under reduced pressure, and drying to obtain the centella asiatica total glycosides. The asiatic pennywort herb total glycosides prepared by the method are relatively high in purity and have very good biological safety.

The present application relates to the field of hydrogel tissue engineering, and particularly relates to an injectable conductive hydrogel and a preparation method and application thereof. The preparation method of the injectable conductive hydrogel comprises the following steps: mixing 7-amino beta cyclodextrin and four-arm polyethylene glycol amino to obtain a complex solution containing a slip ring structure; and mixing the complex solution containing the slip ring structure with a four-arm polyethylene glycol maleimide solution containing silver nanowires. The method for preparing the injectable conductive hydrogel with high mechanical properties is simple, and the prepared hydrogel has high mechanical properties, excellent tensile and compressive deformation capacity and fatigue resistance. The present application provides a new method for the application of the injectable hydrogel in the body.

The application discloses a carbon-coated copper catalyst and a preparation method and application thereof, and relates to the technical field of catalysts; the technical scheme is that beta cyclodextrin is used as a carbon source, so that copper-containing active components are uniformly distributed on a carbon coating layer; wherein, the carbon coating layer derived from cyclodextrin pyrolysis can effectively inhibit the migration and agglomeration of copper active sites, so that the catalyst has higher selectivity and better reaction activity, and the improvement of catalytic performance is promoted; the carbon-coated copper catalyst is suitable for catalyzing the hydrogen production reaction of ethanol aqueous-phase reforming, the hydrogen production rate reaches 35.6 mu mol H2 / gcat / s, the hydrogen selectivity is higher than 99.9%, and long-time continuous and stable operation of the hydrogen production of ethanol aqueous-phase reforming can be ensured.

The invention belongs to the technical field of biomedical materials and biomedical engineering, and discloses self-repairing peach gum hydrogel based on reversible subject-object and boric acid ester bonds, a preparation method and application. The preparation method comprises the following steps: modifying boric acid and amantadine on purified peach gum to obtain boric acid-amantadine peach gum; modifying chitosan with carboxymethyl cyclodextrin to obtain beta cyclodextrin-chitosan; boric acid-amantadine peach gum and beta cyclodextrin-chitosan are mixed, and the self-repairing peach gum hydrogel is obtained through the mutual synergistic effect of a subject, a guest and boric acid ester. The hydrogel has multiple functions of excellent biocompatibility, self-repairing, hemostasis, antibiosis and the like, and can be applied to body surface skin wound repairing.

The application discloses a low-VOC rubber sealing strip and a preparation method thereof in the technical field of rubber sealing materials; the rubber sealing strip comprises the following raw materials according to weight parts: EPDM raw rubber 100 parts, VOC collector 6.2-9.5 parts, toughening agent 12-15 parts, reinforcing agent 36-44 parts, vulcanizing agent 1.7-2.2 parts, accelerator 1.1-1.4 parts, active agent 3.5-4.5 parts and anti-aging agent 0.7-0.9 parts; the VOC collector is formed through substitution reaction of chloro-n-alkyl alcohol and diallylamine, ring-opening and ring-closing reaction of epichlorohydrin, end-epoxy modification, and finally ring-opening grafting of intermediate 2 and beta cyclodextrin; the VOC collector is co-vulcanized with the EPDM matrix, and forms induced-adsorption-bonding collection effect in the vulcanization network, thereby effectively inhibiting the release of VOC.

The application relates to a preparation method of a bromo-beta cyclodextrin and polybenzimidazole composite proton exchange membrane and relates to the technical field of high-temperature proton exchange membrane fuel cells. In order to solve the technical problem that the existing method improves the PA absorption amount but cannot optimize the PA retention capacity, resulting in the decline of the proton conductivity in a short time, the application is characterized by the following steps: 2,2'-(m-phenyl)-5,5'-diphenylbenzimidazole is prepared; bromo-beta cyclodextrin is prepared; and a bromo-beta cyclodextrin and PBI composite membrane is prepared. The prepared proton exchange membrane has multifunctional quaternary ammonium salt, provides more proton hopping sites, can absorb more PA to improve the proton conductivity of the membrane, and has certain acid retention capacity. The application is used for preparing a proton exchange membrane.

The application relates to a preparation method of a cyclodextrin / polycaprolactone-polylactic acid polycaprolactone copolymer inclusion complex microsphere, which comprises the following steps: (1) polycaprolactone, lactide and caprolactone are polymerized under the catalysis of stannous octoate to obtain polycaprolactone-polylactic acid polycaprolactone copolymer; (2) the polycaprolactone-polylactic acid polycaprolactone copolymer is preliminarily dissolved in an acetone solution, and cyclodextrin is dissolved in water; (3) the aqueous solution of cyclodextrin is added dropwise into the acetone solution of the polycaprolactone-polylactic acid polycaprolactone copolymer, and stirring is performed intensively; (4) the mixed solution obtained in the step (3) is continuously stirred at room temperature, washed through acetone and water, and dried to obtain an inclusion complex; and (5) the inclusion complex obtained in the step (4) is dispersed in a solvent to obtain an inclusion complex microsphere. The microsphere prepared by the application has biocompatibility, can be dispersed in various solvents, can be used as a carrier of various drugs, and can also be used as a reinforcing filler of polylactic acid.

The invention discloses a GC-MS (Gas Chromatography-Mass Spectrometer) method for determining the contents of camphor, isoborneol and L-borneol in a concentrated solution for edaravone dextroborneol injection, and belongs to the technical field of pharmaceutical analysis. The method comprises the following steps: preparing a test solution, an impurity stock solution, a reference solution and a system applicability solution by adopting a gas chromatography-mass spectrometry technology; a capillary column using beta cyclodextrin as a stationary liquid is used as a chromatographic column; respectively and precisely measuring the reference solution and the test solution for direct sample injection, recording a chromatogram, and calculating the contents of camphor, isoborneol and L-borneol by peak areas according to an external standard method; the impurities in the concentrated solution for injection of edaravone dextroborneol comprise camphor, isoborneol and L-borneol. The method is high in specificity, sensitivity, accuracy, stability and durability, the quality of the concentrated solution for edaravone dextroborneol injection can be effectively controlled, and medication safety is guaranteed.

The application discloses a sulfobutyl-beta-cyclodextrin / paclitaxel inclusion injection and a preparation method thereof. The inclusion is formed by paclitaxel and sulfobutyl-beta-cyclodextrin with a molar ratio of 1:3, and has the advantages of high drug loading, high encapsulation rate, high water solubility, low toxicity and the like. The application discards toxic cosolvents, eliminates the risk of allergy and toxicity, and has the advantages of simple process, mild conditions, suitability for industrial production, and the like. The obtained preparation is clear, stable, meets the injection requirements, and has the in-vitro antitumor activity equivalent to that of the raw material medicine, so that the application can provide a new preparation for safe clinical use of paclitaxel.